ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,57
0,91%
Dow Jones
38 802,61
0,55%
DAX
18 068,21
0,26%
Brent Oil
83,55
1,74%
Bitcoin
67 029,57
0,59%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Altimmune Inc (ALT)

  7. Altimmune Inc (ALT) Actualités

ALT

Altimmune (ALT)

Altimmune Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALT
DateHeureSourceTitreSymboleSociété
17/06/202411h45PR Newswire (US)The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALTNASDAQ:ALTAltimmune Inc
05/06/202413h00GlobeNewswire Inc.Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)NASDAQ:ALTAltimmune Inc
05/06/202411h45PR Newswire (US)Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALTNASDAQ:ALTAltimmune Inc
29/05/202413h31GlobeNewswire Inc.Altimmune to Participate at Two Upcoming Investor ConferencesNASDAQ:ALTAltimmune Inc
29/05/202413h30GlobeNewswire Inc.Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024NASDAQ:ALTAltimmune Inc
29/05/202411h45PR Newswire (US)The Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming DeadlineNASDAQ:ALTAltimmune Inc
21/05/202415h00PR Newswire (US)Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)NASDAQ:ALTAltimmune Inc
21/05/202411h45PR Newswire (US)The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALTNASDAQ:ALTAltimmune Inc
14/05/202411h45PR Newswire (US)Contact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)NASDAQ:ALTAltimmune Inc
10/05/202411h45PR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) ShareholdersNASDAQ:ALTAltimmune Inc
09/05/202423h51PR Newswire (US)INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law FirmNASDAQ:ALTAltimmune Inc
09/05/202422h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALTAltimmune Inc
09/05/202413h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALTAltimmune Inc
09/05/202413h00GlobeNewswire Inc.Altimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
02/05/202413h30GlobeNewswire Inc.Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024NASDAQ:ALTAltimmune Inc
01/05/202413h30GlobeNewswire Inc.Altimmune to Participate at Two Upcoming ConferencesNASDAQ:ALTAltimmune Inc
25/04/202423h24GlobeNewswire Inc.Altimmune Statement on the Passing of Dr. Stephen HarrisonNASDAQ:ALTAltimmune Inc
27/03/202412h00GlobeNewswire Inc.Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALTAltimmune Inc
27/03/202411h57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:ALTAltimmune Inc
20/03/202412h30GlobeNewswire Inc.Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024NASDAQ:ALTAltimmune Inc
14/02/202418h04Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALTAltimmune Inc
06/02/202400h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALTAltimmune Inc
26/01/202417h49Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALTAltimmune Inc
02/01/202413h30GlobeNewswire Inc.Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024NASDAQ:ALTAltimmune Inc
08/12/202314h35GlobeNewswire Inc.Water Tower Research US Climate Virtual Investor Conference: Presentations Now Available for Online ViewingNASDAQ:ALTAltimmune Inc
04/12/202314h35GlobeNewswire Inc.Water Tower Research US Climate Investor Conference Agenda Announced for December 7th, 2023NASDAQ:ALTAltimmune Inc
30/11/202322h24GlobeNewswire Inc.Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of PemvidutideNASDAQ:ALTAltimmune Inc
07/11/202313h00GlobeNewswire Inc.Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
31/10/202312h30GlobeNewswire Inc.Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023NASDAQ:ALTAltimmune Inc
26/10/202314h15Dow Jones NewsAltimmune Gets FDA Fast-Track Designation for Pemvidutide in NASHNASDAQ:ALTAltimmune Inc
 Showing the most relevant articles for your search:NASDAQ:ALT

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
EU
ACA
Credit Agricole
NYSE
KO
Coca Cola
EU
AI
Air Liquide
NYSE
JPM
JP Morgan Chase
EU
BNP
BNP Paribas
EU
DG
Vinci
COIN
BTCUSD
Bitcoin
NASDAQ
MSFT
Microsoft
NYSE
MRK
Merck
EU
LR
Legrand
EU
VIV
Vivendi
SPI
SP500
S&P 500
EU
RI
Pernod Ricard
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés